Kawin Technology(SH:688687) EBSCN·2025-08-20 10:26Investment Rating - The report maintains a "Buy" rating for the company [5] Core Viewpoints - The company reported a revenue of 566 million yuan for H1 2025, a decrease of 5.05% year-on-year, while the net profit attributable to the parent company increased by 11.75% to 47 million yuan [1] - The company is increasing its R&D investment, with R&D expenses reaching 71.41 million yuan in H1 2025, a year-on-year increase of 1.22%, accounting for 12.61% of revenue [2] - Several products are in clinical stages, including the KW-040 siRNA drug for hepatitis B, which has submitted a clinical trial application, and multiple other projects in phase II trials [2] - The company is solidifying its market position with mature products, maintaining a leading market share in interferon α2b formulations, and has initiated bulk purchasing in nearly 30 provinces [3] - The profit forecast for 2025-2027 has been adjusted downwards, with net profit estimates of 161 million, 216 million, and 238 million yuan respectively, reflecting a decrease of 6%, 2%, and 3% from previous estimates [3] Summary by Sections Financial Performance - H1 2025 revenue was 566 million yuan, down 5.05% year-on-year; net profit was 47 million yuan, up 11.75% [1] - R&D expenses were 71.41 million yuan, up 1.22% year-on-year, representing 12.61% of revenue [2] Clinical Development - The company is pursuing multiple clinical studies across various diseases, with several projects in advanced clinical stages [2] - Notable projects include KW-040 for hepatitis B and others targeting herpes, shingles, and warts [2] Market Position - The company maintains a strong market presence with its mature products, particularly in the interferon segment, and has successfully implemented bulk purchasing strategies [3] Profit Forecast and Valuation - Revised net profit forecasts for 2025-2027 are 161 million, 216 million, and 238 million yuan, with corresponding P/E ratios of 39, 29, and 27 [3]